Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Malignant Solid Neoplasm: early-phase trial registry
9 of 60 indexed Refractory Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #235 of 28,707 conditions by registered trial count.
60 US clinical trials · 9 currently recruiting · #235 of 28,707 conditions by registered trial count
Refractory Malignant Solid Neoplasm: 60 US clinical trials tracked, 9 recruiting.
Refractory Malignant Solid Neoplasm is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 45 of these trials.
Enrollment posture brief
Registry condition refractory-malignant-solid-neoplasm
OPEN 9 | RECR 15% | LATE 0 | EARLY 59 | RANK #235 | SPON 45
Volume-matched condition peers
Nearest open-share peer: Coronary Heart Disease (15% recruiting · 20 trials)
Refractory Malignant Solid Neoplasm lists 9 open slots (15% of 60 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Malignant Solid Neoplasm is recruiting below its size-band peers.
9 of 60 indexed trials (15%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Malignant Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 45 of 60 trials (75%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 60 trials that report a genuine target (sentinel values excluded). 58 of those (96.7%) plan for fewer than 100 participants.
-
Refractory Malignant Solid Neoplasm research is mostly interventional.
60 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
60 total, page 1 of 2
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT06223542
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05227326
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Children's Oncology Group
NCT06620302
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT04870944
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05053971
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
NCT06911008
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
NCT06320405
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
NCT05791448
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
NCT05455606
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT02079740
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
NCT03065387
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439175
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02595931
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT04294628
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
NCT04439344
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
NCT04439318
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
NCT03537690
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
NCT06390865
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
NCT06357975
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT05038839
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
NCT06390839
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
NCT04439136
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
NCT04439201
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT05554341
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
NCT04439110
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
NCT06400238
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
NCT06390852
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
NCT04439227
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
NCT04439331
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
NCT06357988
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
NCT04439188
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
NCT04439279
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
NCT05490771
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
NCT06308822
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
NCT04439123
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
National Cancer Institute (NCI)
NCT01303341
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
NCT06385496
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
National Cancer Institute (NCI)
NCT06400225
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
NCT04439292
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
NCT06400251
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05071209
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
NCT02535312
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
NCT03878095
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
NCT04439149
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
NCT04266912
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
NCT06360575
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
NCT01364051
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
NCT06385483
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 33 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Malignant Solid Neoplasm page
60 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Refractory Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Refractory Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Malignant Solid Neoplasm condition card totals 60 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.